Hematopoietic stem-cell transplantation in children with refractory acute myeloid leukemia

Yasuhiro Okamoto, Kazuko Kudo, Ken Tabuchi, Daisuke Tomizawa, Takashi Taga, Hiroaki Goto, Hiromasa Yabe, Yozo Nakazawa, Katsuyoshi Koh, Kazuhiro Ikegame, Nao Yoshida, Naoyuki Uchida, Kenichiro Watanabe, Yuhki Koga, Masami Inoue, Koji Kato, Yoshiko Atsuta, Hiroyuki Ishida

Research output: Contribution to journalArticle

Abstract

Allogeneic hematopoietic stem cell transplantation (HSCT) can be used to treat children with refractory acute myeloid leukemia (AML). This retrospective analysis aimed to describe the outcomes and risk factors in such children. Data were collected through the nation-wide registry program in Japan. A total of 417 AML (median age: 13 years) patients 20 years or younger at HSCT, between January 2001 and December 2015, were included. A total of 314 patients died, and the median follow-up duration of the survivors was 1052 days. The most frequent cause of death was leukemia progression (58%). The 3-year overall survival (OS) rate was 23% (95% confidence interval [CI]: 19–28%). Chronic GVHD was associated with improved 3-year OS (47%, 95% CI, 36–57%, hazard ratio: 0.603, p = 0.001). Low performance status, presence of more than 25% of marrow blasts, presence of blasts in the blood at transplantation, FAB (other than M1 or M2), male donors, and number of transplantations ≥ 2 were adverse pre-HSCT variables. Patients with 0, 1–2, 3–4, 5, and 6–7 pre-HSCT variables had 3-year OS rates of 52%, 32%, 19%, 8, and 0%, respectively. Our findings may help experts decide if HSCT should be performed in such cases.

Original languageEnglish
Pages (from-to)1489-1498
Number of pages10
JournalBone Marrow Transplantation
Volume54
Issue number9
DOIs
Publication statusPublished - Sep 1 2019

Fingerprint

Hematopoietic Stem Cell Transplantation
Acute Myeloid Leukemia
Survival Rate
Transplantation
Confidence Intervals
Survivors
Registries
Cause of Death
Japan
Leukemia
Bone Marrow
Tissue Donors
Survival

All Science Journal Classification (ASJC) codes

  • Hematology
  • Transplantation

Cite this

Okamoto, Y., Kudo, K., Tabuchi, K., Tomizawa, D., Taga, T., Goto, H., ... Ishida, H. (2019). Hematopoietic stem-cell transplantation in children with refractory acute myeloid leukemia. Bone Marrow Transplantation, 54(9), 1489-1498. https://doi.org/10.1038/s41409-019-0461-0

Hematopoietic stem-cell transplantation in children with refractory acute myeloid leukemia. / Okamoto, Yasuhiro; Kudo, Kazuko; Tabuchi, Ken; Tomizawa, Daisuke; Taga, Takashi; Goto, Hiroaki; Yabe, Hiromasa; Nakazawa, Yozo; Koh, Katsuyoshi; Ikegame, Kazuhiro; Yoshida, Nao; Uchida, Naoyuki; Watanabe, Kenichiro; Koga, Yuhki; Inoue, Masami; Kato, Koji; Atsuta, Yoshiko; Ishida, Hiroyuki.

In: Bone Marrow Transplantation, Vol. 54, No. 9, 01.09.2019, p. 1489-1498.

Research output: Contribution to journalArticle

Okamoto, Y, Kudo, K, Tabuchi, K, Tomizawa, D, Taga, T, Goto, H, Yabe, H, Nakazawa, Y, Koh, K, Ikegame, K, Yoshida, N, Uchida, N, Watanabe, K, Koga, Y, Inoue, M, Kato, K, Atsuta, Y & Ishida, H 2019, 'Hematopoietic stem-cell transplantation in children with refractory acute myeloid leukemia', Bone Marrow Transplantation, vol. 54, no. 9, pp. 1489-1498. https://doi.org/10.1038/s41409-019-0461-0
Okamoto, Yasuhiro ; Kudo, Kazuko ; Tabuchi, Ken ; Tomizawa, Daisuke ; Taga, Takashi ; Goto, Hiroaki ; Yabe, Hiromasa ; Nakazawa, Yozo ; Koh, Katsuyoshi ; Ikegame, Kazuhiro ; Yoshida, Nao ; Uchida, Naoyuki ; Watanabe, Kenichiro ; Koga, Yuhki ; Inoue, Masami ; Kato, Koji ; Atsuta, Yoshiko ; Ishida, Hiroyuki. / Hematopoietic stem-cell transplantation in children with refractory acute myeloid leukemia. In: Bone Marrow Transplantation. 2019 ; Vol. 54, No. 9. pp. 1489-1498.
@article{245a130c9f884cc3b17ef4c851b70613,
title = "Hematopoietic stem-cell transplantation in children with refractory acute myeloid leukemia",
abstract = "Allogeneic hematopoietic stem cell transplantation (HSCT) can be used to treat children with refractory acute myeloid leukemia (AML). This retrospective analysis aimed to describe the outcomes and risk factors in such children. Data were collected through the nation-wide registry program in Japan. A total of 417 AML (median age: 13 years) patients 20 years or younger at HSCT, between January 2001 and December 2015, were included. A total of 314 patients died, and the median follow-up duration of the survivors was 1052 days. The most frequent cause of death was leukemia progression (58{\%}). The 3-year overall survival (OS) rate was 23{\%} (95{\%} confidence interval [CI]: 19–28{\%}). Chronic GVHD was associated with improved 3-year OS (47{\%}, 95{\%} CI, 36–57{\%}, hazard ratio: 0.603, p = 0.001). Low performance status, presence of more than 25{\%} of marrow blasts, presence of blasts in the blood at transplantation, FAB (other than M1 or M2), male donors, and number of transplantations ≥ 2 were adverse pre-HSCT variables. Patients with 0, 1–2, 3–4, 5, and 6–7 pre-HSCT variables had 3-year OS rates of 52{\%}, 32{\%}, 19{\%}, 8, and 0{\%}, respectively. Our findings may help experts decide if HSCT should be performed in such cases.",
author = "Yasuhiro Okamoto and Kazuko Kudo and Ken Tabuchi and Daisuke Tomizawa and Takashi Taga and Hiroaki Goto and Hiromasa Yabe and Yozo Nakazawa and Katsuyoshi Koh and Kazuhiro Ikegame and Nao Yoshida and Naoyuki Uchida and Kenichiro Watanabe and Yuhki Koga and Masami Inoue and Koji Kato and Yoshiko Atsuta and Hiroyuki Ishida",
year = "2019",
month = "9",
day = "1",
doi = "10.1038/s41409-019-0461-0",
language = "English",
volume = "54",
pages = "1489--1498",
journal = "Bone Marrow Transplantation",
issn = "0268-3369",
publisher = "Nature Publishing Group",
number = "9",

}

TY - JOUR

T1 - Hematopoietic stem-cell transplantation in children with refractory acute myeloid leukemia

AU - Okamoto, Yasuhiro

AU - Kudo, Kazuko

AU - Tabuchi, Ken

AU - Tomizawa, Daisuke

AU - Taga, Takashi

AU - Goto, Hiroaki

AU - Yabe, Hiromasa

AU - Nakazawa, Yozo

AU - Koh, Katsuyoshi

AU - Ikegame, Kazuhiro

AU - Yoshida, Nao

AU - Uchida, Naoyuki

AU - Watanabe, Kenichiro

AU - Koga, Yuhki

AU - Inoue, Masami

AU - Kato, Koji

AU - Atsuta, Yoshiko

AU - Ishida, Hiroyuki

PY - 2019/9/1

Y1 - 2019/9/1

N2 - Allogeneic hematopoietic stem cell transplantation (HSCT) can be used to treat children with refractory acute myeloid leukemia (AML). This retrospective analysis aimed to describe the outcomes and risk factors in such children. Data were collected through the nation-wide registry program in Japan. A total of 417 AML (median age: 13 years) patients 20 years or younger at HSCT, between January 2001 and December 2015, were included. A total of 314 patients died, and the median follow-up duration of the survivors was 1052 days. The most frequent cause of death was leukemia progression (58%). The 3-year overall survival (OS) rate was 23% (95% confidence interval [CI]: 19–28%). Chronic GVHD was associated with improved 3-year OS (47%, 95% CI, 36–57%, hazard ratio: 0.603, p = 0.001). Low performance status, presence of more than 25% of marrow blasts, presence of blasts in the blood at transplantation, FAB (other than M1 or M2), male donors, and number of transplantations ≥ 2 were adverse pre-HSCT variables. Patients with 0, 1–2, 3–4, 5, and 6–7 pre-HSCT variables had 3-year OS rates of 52%, 32%, 19%, 8, and 0%, respectively. Our findings may help experts decide if HSCT should be performed in such cases.

AB - Allogeneic hematopoietic stem cell transplantation (HSCT) can be used to treat children with refractory acute myeloid leukemia (AML). This retrospective analysis aimed to describe the outcomes and risk factors in such children. Data were collected through the nation-wide registry program in Japan. A total of 417 AML (median age: 13 years) patients 20 years or younger at HSCT, between January 2001 and December 2015, were included. A total of 314 patients died, and the median follow-up duration of the survivors was 1052 days. The most frequent cause of death was leukemia progression (58%). The 3-year overall survival (OS) rate was 23% (95% confidence interval [CI]: 19–28%). Chronic GVHD was associated with improved 3-year OS (47%, 95% CI, 36–57%, hazard ratio: 0.603, p = 0.001). Low performance status, presence of more than 25% of marrow blasts, presence of blasts in the blood at transplantation, FAB (other than M1 or M2), male donors, and number of transplantations ≥ 2 were adverse pre-HSCT variables. Patients with 0, 1–2, 3–4, 5, and 6–7 pre-HSCT variables had 3-year OS rates of 52%, 32%, 19%, 8, and 0%, respectively. Our findings may help experts decide if HSCT should be performed in such cases.

UR - http://www.scopus.com/inward/record.url?scp=85061077062&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85061077062&partnerID=8YFLogxK

U2 - 10.1038/s41409-019-0461-0

DO - 10.1038/s41409-019-0461-0

M3 - Article

VL - 54

SP - 1489

EP - 1498

JO - Bone Marrow Transplantation

JF - Bone Marrow Transplantation

SN - 0268-3369

IS - 9

ER -